Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 11/20 | 0.62 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.51 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | PRCP | P42785 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 2/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17529970 | 0.81 | CCR1 (0.44) | CCR1CTSLCTSKCTSSCCKBR | |
| SCHEMBL17529976 | 0.79 | CTSS (0.62) | CCR1CTSLCTSKCTSSCTSB | |
| SCHEMBL17530018 | 0.77 | CCR1 (0.42) | CCR1CTSLCTSKCTSSCTSB | |
| SCHEMBL2160363 | 0.77 | CCR1 (1.00) | CCR1KCNH2 | |
| SCHEMBL13588778 | 0.75 | KCNH2 (0.64) | CCR1KCNH2HRH3 | |
| SCHEMBL17530007 | 0.73 | CTSL (0.62) | CTSLCTSKCTSSCTSB | |
| SCHEMBL2159331 | 0.73 | CCR1 (0.90) | CCR1KCNH2 | |
| SCHEMBL2159737 | 0.72 | CCR1 (0.84) | CCR1KCNH2 | |
| SCHEMBL10291892 | 0.71 | CCR1 (1.00) | CCR1KCNH2 | |
| SCHEMBL2159263 | 0.71 | CCR1 (0.85) | CCR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016027284-A2 | PIPERIDINE UREAS AS CATHEPSIN CYSTEINE PROTEASE INHIBITORS | ALKEM LABORATORIES LTD. (IN) | 2016-02-25 | — | — | WO | disclosed |